OXIGENE'S CA4P RECEIVES OK IN UK

Oxigene has received regulatory clearance in the UK to begin its first Phase III clinical trial with its lead product candidate, Combretastatin A4P (CA4P).

The study will be a randomized, double blind, placebo-controlled trial. The trial is expected to enroll approximately 370 patients who have not had prior treatment for non-small cell lung cancer and who will be randomized into either a control group or a treatment group. The primary objective of this trial is to compare median survival time of patients in the treatment group versus the control group.